Skin cancer and wound healing: Tissue-specific similarities in extracelluar proteolysis

APMIS, Supplement

Volumn 111, Issue 107, 2003, Pages 5-36

  Rømer, John ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

MATRIX METALLOPROTEINASE; PLASMINOGEN; PROTEINASE; TUMOR NECROSIS FACTOR ALPHA;

BREAST CARCINOMA; CANCER INVASION; CARCINOGENESIS; COLON CARCINOMA; GRANULATION TISSUE; HUMAN; IN SITU HYBRIDIZATION; KERATINOCYTE; MAMMARY GLAND FUNCTION; NEUTROPHIL; NONHUMAN; PHENOTYPE; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVIEW; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA; WOUND HEALING; XENOGRAFT;

EID: 0043162163     PISSN: 0903465X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (214)

1. Aguirre-Ghiso J. A., Liu D., Mignatti A., Kovalski K., and Ossowski L. (2001) Urokinase receptor and fibronectin regulate the ERKMAPK to p38MAPK activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol Biol Cell 12, 863-879.
2. Airola K., Johansson N., Kariniemi A. L., Kahari V. M., and Saarialho-Kere U. K. (1997) Human collagenase-3 is expressed in malignant squamous epithelium of the skin. J Invest Dermatol 109, 225-231.
3. Akhurst R. J. and Balmain A. (1999) Genetic events and the role of TGF beta in epithelial tumour progression. J Pathol 187, 82-90.
4. Akhurst R. J., Fee F., and Balmain A. (1988) Localized production of TGF-beta mRNA in tumour promoter-stimulated mouse epidermis. Nature 331, 363-365.
5. Andreasen P. A., Egelund R., and Petersen H. H. (2000) The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 57, 25-40.
6. Andreasen P. A., Georg B., Lund L. R., Riccio A., and Stacey S. N. (1990) Plasminogen activator inhibitors: Hormonally regulated serpins. Mol Cell Endocrinol 68, 1-19.
7. Asch P. H., Basset P., Roos M., Grosshans E., Bellocq J. P., and Cribier B. (1999) Expression of stromelysin 3 in keratoarcanthoma and squamous cell carcinoma. Am J Dermatopathol 21, 146-150.
8. Ashcroft G.S., Yang X., Glick A.B., Weinstein M., Letterio J.L., Mizel D.E., Anzano M., Greenwell-Wild T., Wahl S.M., Deng C., and Roberts A.B. (1999) Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response. Nature Cell Biol 1, 260-266.
9. Bach-Gansmo E. T., Halvorsen S., Godal H. C., and Skjonsberg O. H. (1994) Degradation of the alpha-chain of fibrin by human neutrophil elastase reduces the stimulating effect of fibrin on plasminogen activation. Thromb Res 75, 307-317.
10. Balmain A. and Harris C. C. (2000) Carcinogenesis in mouse and human cells: parallels and paradoxes. Carcinogenesis 21, 371-377.
11. Balslev E., Thomsen H. K., Danielsen L., and Warburg F. (1992) The occurrence of pericapillary fibrin in venous hypertension and ischaemic leg ulcers: a histopathological study. Br J Dermatol 126, 582-585.
12. Basset P., Wolf C., and Chambon P. (1993) Expression of the stromelysin-3 gene in fibroblastic cells of invasive carcinomas of the breast and other human tissues: a review. Breast Cancer Res Treat 24, 185-193.
13. Bateman J. B., Pettit T H., Isenberg S. J., and Simons K. B. (1986) Ligneous conjunctivitis: an autosomal recessive disorder. J Pediatr Ophthalmol Strabismus 23, 137-140.
14. Bechtel M. J., Reinartz J., Rox J. M., Inndorf S., Schaefer B. M., and Kramer M. D. (1996) Upregulation of cell-surface-associated plasminogen activation in cultured keratinocytes by interleukin-1 beta and tumor necrosis factor-alpha. Exp Cell Res 223, 395-404.
15. Bechtel M. J., Wysocki N. S., Heidtmann A., Stark H. J., Fusenig N., Kramer M. D., and Schaefer B. M. (1998) Plasminogen activator inhibitor type 2 is expressed in keratinocytes during re-epithelialization of epidermal defects. Br J Dermatol 138, 22-28.
16. Behrendt N., Jensen O. N., Engelholm L. H., Mortz E., Mann M., and Danø K. (2000) A urokinase receptor-associated protein with specific collagen binding properties. J Biol Chem 275, 1993-2002.
17. Behrendt N., Rønne E., Ploug M., Petri T., Løber D., Nielsen L. S., Schleuning W. D., Blasi F., Appella E., and Danø K. (1990) The human receptor for urokinase plasminogen activator. NH2- terminal amino acid sequence and glycosylation variants. J Biol Chem 265, 6453-6460.
18. Behrendt N. and Stephens R. W. (1998) The urokinase receptor. Fibrinolysis Proteolysis 12, 191-204.
19. Belin D., Wohlwend A., Schleuning W. D., Kruithof E. K. O., and Vassalli J. D. (1989) Facultative polypeptide translocation allows a single mRNA to encode the secreted and cytosolic forms of plasminogen activators inhibitor 2. EMBO J 8, 3287-3294.
20. Bini A., Itoh Y., Kudryk B. J., and Nagase H. (1996) Degradation of cross-linked fibrin by matrix metalloproteinase 3 (stromelysin 1): hydrolysis of the gamma Gly 404-Ala 405 peptide bond. Biochemistry 35, 13056-13063.
21. Blasi F. (1993) Urokinase and urokinase receptor: a paracrine/autocrine system regulating cell migration and invasiveness. Bioessays 15, 105-111.
22. Blasi F. (1999) Proteolysis, cell adhesion, chemotaxis, and invasiveness are regulated by the u-PA-u-PAR-PAI-1 system. Thromb Haemost 82, 298-304.
23. Blasi F., Vassalli J. D., and Danø K. (1987) Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors. J Cell Biol 104, 801-804.
24. Brew K., Dinakarpandian D., and Nagase H. (2000) Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 1477, 267-283.
25. Brünner N., Thompson E. W., Spang-Thomsen M., Rygaard J., Danø K., and Zwiebel J. A. (1992) lacZ transduced human breast cancer xenografts as an in vivo model for the study of invasion and metastasis. Eur J Cancer 28, 1989-1995.
26. Bugge T. H., Flick M. J., Daugherty C. C., and Degen J. L. (1995) Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. Genes & development 9, 794-807.
27. Bugge T. H., Kombrinck K. W., Flick M. J., Daugherty C. C., Danton M. J., and Degen J. L. (1996) Loss of fibrinogen rescues mice from the pleiotropic effects of plasminogen deficiency. Cell 87, 709-719.
28. Bugge T. H., Lund L. R., Kombrinck K. K., Nielsen B. S., Holmbäck K., Drew A. F., Flick M. J., Witte D. P., Danø K., and Degen J. L. (1998) Reduced metastasis of Polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice. Oncogene 16, 3097-3104.
29. Butler G. S., Butler M. J., Atkinson S. J., Will H., Tamura T., van Westrum S. S., Crabbe. T., Clements J., d'Ortho M. P., and Murphy G. (1998) The TIMP2 membrane type 1 metalloproteinase "receptor" regulates the concentration and efficient activation of progelatinase A. A kinetic study. J Biol Chem 273, 871-880.
30. Camerer E., Gjernes E., Wiiger M., Pringle S., and Prydz H. (2000) Binding of factor VIIa to tissue factor on keratinocytes induces gene expression. J Biol Chem 275, 6580-6585.
31. Carmeliet P., Moons L., Lijnen R., Baes M., Lemaitre V., Tipping P., Drew A., Eeckhout Y., Shapiro S., Lupu F., and Collen D. (1997) Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat Genet 17, 439-444.
32. Chan J. C. Y., Duszczyszyn D. A., Castellino F. J., Ploplis V. A. (2001) Accelerated skin wound healing in plasminogen activator inhibitor-1-deficient mice. Am J Pathol 159, 1681-1688.
33. Chenard M. P., O'Siorain L., Shering S., Rouyer N., Lutz Y., Wolf C., Basset P., Bellocq J. P., and Duffy M. J. (1996) High levels of stromelysin-3 correlate with poor prognosis in patients with breast carcinoma. Int J Cancer 69, 448-451.
34. Clark R. A. F. (Editor) (1996). The Molecular and Cellular Biology of Wound Repair. 2nd edition, Plenum Pub. Corp.
35. Collen D. (1993) Towards improved thrombolytic therapy. Lancet 342, 34-36.
36. Crowley C. W., Cohen R. L., Lucas B. K., Liu G., Shuman M. A., and Levinson A. D. (1993) Prevention of metastasis by inhibition of the urokinase receptor. Proc Natl Acad Sci USA 90, 5021-5025.
37. Danø K., Andreasen P. A., Grøndahl-Hansen J., Kristensen P., Nielsen L. S., and Skriver L. (1985) Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 44, 139-266.
38. Danø K., Behrendt N., Brünner N., Ellis V., Ploug M., and Pyke C. (1994) The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion. Fibrinolysis 8, 189-203.
39. Danø K., Rømer J., Nielsen B. S., Bjørn S., Pyke C., Rygaard J., and Lund L. R. (1999) Cancer invasion and tissue remodeling-cooperation of protease systems and cell types. APMIS 107, 120-127.
40. Dear A. E. and Medcalf R. L. (1995) The cellular and molecular biology of plasminogen activator inhibitor type-2. Fibrinolysis 9, 321-330.
41. Devalaraja R. M., Nanney L. B., Qian Q., Du J., Yu Y., Devalaraja M. N., and Richmond A. (2000) Delayed wound healing in CXCR2 knockout mice. J Invest Dermatol 115, 234-244.
42. Donaldson D. J. and Mahan J. T. (1988) Keratinocyte migration and the extracellular matrix. J Invest Dermatol 90, 623-628.
43. Drew A. F., Kaufman A. H., Kombrinck K. W., Danton M. J., Daugherty C. C., Degen J. L., and Bugge T. H. (1998) Ligneous conjunctivitis in plasminogen-deficient mice. Blood 91, 1616-1624.
44. Drew A. F., Liu H., Davidson J. M., Daugherty C. C., and Degen J. L. (2001) Wound-healing defects in mice lacking fibrinogen. Blood 97, 3691-3698.
45. Duffy M. J., O'Grady P., Devaney D., O'Siorain L., Fennelly J. J., and Lijnen H. J. (1988) Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report. Cancer 62, 531-533.
46. Dvorak H. F. (1986) Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 315, 1650-1659.
47. Ellis V., Behrendt N., and Danø K. (1991) Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor. J Biol Chem 266, 12752-12758.
48. Ellis V., Ploug M., Plesner T., and Danø K. (1996) Gene expression and function of the cellular receptor for u-PA (u-PAR), in Fibrinolysis in Disease (Glas-Greenwalt P., ed.), CRC Press.
49. Engelholm L. H., Nielsen B. S., Netzel-Arnett S., Solberg H., Chen X. D., Lopez-Garcia J. M., Lopez-Otin C., Young M. F., Birkedal-Hansen H., Danø K., Lund L. R., Behrendt N., and Bugge T. H. (2001) The urokinase plasminogen activator receptor-associated protein/endo180 is coexpressed with its interaction partners urokinase plasminogen activator receptor and matrix metalloprotease-13 during osteogenesis. Lab Invest 81, 1403-1414.
50. Eriksen J., Kristensen P., Pyke C., and Danø K. (1989) Plasminogen activator inhibitor (type-1) in rat adrenal medulla. Histochemistry 92, 377-383.
51. Falanga V. (1993) Venous ulceration. J Dermatol Surg Oncol 19, 764-771.
52. Falanga V., Kirsner R., Katz M. H., Gould E., Eaglstein W. H., and McFalls S. (1992) Pericapillary fibrin cuffs in venous ulceration. Persistence with treatment and during ulcer healing. J Dermatol Surg Oncol 18, 409-414.
53. Falanga V. and Sabolinski M. (1999) A bilayered living skin construct (APLIGRAF (TM)) accelerates complete closure of hard-to-heal venous ulcers. Wound Repair Regen 7, 201-207.
54. Foekens J. A., Peters H. A., Look M. P., Portengen H., Schmitt M., Kramer M. D., Brünner N., Janicke F., Meijervan-Gelder M. E., Henzen-Logmans S. C., van Putten W. L., and-Klijn J. G. (2000) The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res 60, 636-643.
55. Frame S. and Balmain A. (1999) Target genes and target cells in carcinogenesis. Br J Cancer 80, 28-33.
56. Frandsen T. L., Holst-Hansen C., Nielsen B. S., Christensen I. J., Nyengaard J. R., Carmeliet P., and Brünner N. (2001) Direct evidence of the importance of stromal urokinase plasminogen activator (uPA) in the growth of an experimental human breast cancer using a combined uPA gene-disrupted and immunodeficient xenograft model. Cancer Res 61, 532-537.
57. Gaardsvoll H., Danø K., and Ploug M. (1999) Mapping part of the functional epitope for ligand binding on the receptor for urokinase-type plasminogen activator by site-directed mutagenesis. J Biol Chem 274, 37995-38003.
58. Gillitzer R. and Goebeler M. (2001) Chemokines in cutaneous wound healing. J Leukoc Biol 69, 513-521.
59. Goldfinger L. E., Hopkinson S. B., deHart G. W., Collawn S., Couchman J. R., and Jones J. C. (1999) The alpha3 laminin subunit, alpha6beta4 and alpha3beta1 integrin coordinately regulate wound healing in cultured epithelial cells and in the skin. J Cell Sci 112, 2615-2629.
60. Goldfinger L. E., Stack M. S., and Jones J. C. (1998) Processing of laminin-5 and its functional consequences: role of plasmin and tissue-type plasminogen activator. J Cell Biol 141, 255-265.
61. Gray S. T., Yun K., Motoori T., and Kuys Y. M. (1993) Interstitial collagenase gene expression in colonic neoplasia. Am J Pathol 143, 663-671.
62. Grobelny D., Poncz L., and Galardy R. E. (1992) Inhibition of human skin fibroblast collagenase, thermolysin, and Pseudomonas aeruginosa elastase by peptide hydroxamic acids. Biochemistry 31, 7152-7154.
63. Grøndahl-Hansen J., Christensen I. J., Rosenquist C., Brünner N., Mouridsen H. T., Danø K., and Blichert-Toft M. (1993) High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 53, 2513-2521.
64. Grøndahl-Hansen J., Lund L. R., Ralfkiær E., Ottevanger V., and Danø K. (1988) Urokinase- and tissue-type plasminogen activators in keratinocytes during wound reepithelialization in vivo. J Invest Dermatol 90, 790-795.
65. Grøndahl-Hansen J., Peters H. A., van Putten W. L., Look M. P., Pappot H., Rønne E., Danø K., Klijn J. G., Brünner N., and Foekens J. A. (1995) Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin Cancer Res 1, 1079-1087.
66. Grøndahl-Hansen J., Ralfkiær E., Kirkeby L. T., Kristensen P., Lund L. R., and Danø K. (1991) Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans. Am J Pathol 138, 111-117.
67. Guy C. T., Cardiff R. D., and Muller W. J. (1992) Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 12, 954-961.
68. Heiss, M. M., Allgayer, H., Gruetzner, K. U., Funke, I., Babic, R., Jauch, K. W., and Schildberg, F. W. (1995) Individual development and uPA-receptor expression of disseminated tumour cells in bone marrow: a reference to early systemic disease in solid cancer. Nature Med 1, 1035-1039.
69. Heppner K. J., Matrisian L. M., Jensen R. A., and Rodgers W. H. (1996) Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. Am J Pathol 149, 273-282.
70. Hernandez-Barrantes S., Toth M., Bernardo M. M., Yurkova M., Gervasi D. C., Raz Y., Sang Q. A., and Fridman R. (2000) Binding of active (57 kDa) membrane type 1-matrix metalloproteinase (MT1-MMP) to tissue inhibitor of metalloproteinase (TIMP)-2 regulates MT1-MMP processing and pro-MMP-2 activation. J Biol Chem 275, 12080-12089.
71. Hiraoka N., Allen E., Apel I. J., Gyetko M. R., and Weiss S. J. (1998) Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. Cell 95, 365-377.
72. Hoffman R., Starkey S., and Coad J. (1998) Wound fluid from venous leg ulcers degrades plasminogen and reduces plasmin generation by keratinocytes. J Invest Dermatol 111, 1140-1144.
73. Hübner G., Brauchle M., Smola H., Madlener M., Fassler R., and Werner S. (1996) Differential regulation of pro-inflammatory cytokines during wound healing in normal and glucocorticoid-treated mice. Cytokine 8, 548-556.
74. Høyer-Hansen G., Behrendt N., Ploug M., Danø K., and Preissner K. T. (1997) The intact urokinase receptor is required for efficient vitronectin binding: receptor cleavage prevents ligand interaction. FEBS Lett 420, 79-85.
75. Isseroff R. R., Fusenig N. E., and Rifkin D. B. (1983) Plasminogen activator in differentiating mouse keratinocytes. J Invest Dermatol 80, 217-222.
76. Itoh Y., Kajita M., Kinoh H., Mori H., Okada A., and Seiki M. (1999a) Membrane type 4 matrix metalloproteinase (MT4-MMP, MMP-17) is a glycosylphosphati-dylinositol-anchored proteinase. J Biol Chem 274, 34260-34266.
77. Itoh T., Tanioka M., Matsuda H., Nishimoto H., Yoshioka T., Suzuki R., and Uehira M. (1999b) Experimental metastasis is suppressed in MMP-9-deficient mice. Clin Exp Metastasis 17, 177-181.
78. Itoh T., Tanioka M., Yoshida H., Yoshioka T., Nishimoto H., and Itohara S. (1998) Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res 58, 1048-1051.
79. Kim J., Yu W., Kovalski K., and Ossowski L. (1998) Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay. Cell 94, 353-362.
80. Kinoshita T., Sato H., Okada A., Ohuchi E., Imai K., Okada Y., and Seiki M. (1998) TIMP-2 promotes activation of progelatinase A by membrane-type 1 matrix metalloproteinase immobilized on agarose beads. J Biol Chem 273, 16098-16103.
81. Kojima S., Itoh Y., Matsumoto S. I., Masuho Y., and Seiki M. (2000) Membrane-type 6 matrix metalloproteinase (MT6-MMP, MMP-25) is the second glycosyl-phosphatidyl inositol (GPI)-anchored MMP. FEBS Lett 480, 142-146.
82. Kook Y. H., Adamski J., Zelent A., and Ossowski L. (1994) The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy. EMBO J 13, 3983-3991.
83. Kristensen P., Eriksen J., Blasi F., and Danø K. (1991) Two alternatively spliced mouse urokinase receptor mRNAs with different histological localization in the gastrointestinal tract. J Cell Biol 115, 1763-1771.
84. Kruithof E. K., Tran-Thang C., and Bachmann F. (1986) Studies on the release of a plasminogen activator inhibitor by human platelets. Thromb Haemost 55, 201-205.
85. Larsson L.I., Skriver L., Nielsen L.S., Grøndahl-Hansen J., Kristensen P., and Danø K. (1984) Distribution of urokinase-type plasminogen activator immunoreactivity in the mouse. J Cell Biol 98, 894-903.
86. Lefebvre O., Wolf C., Limacher J. M., Hutin P., Wendling C., LeMeur M., Basset P., and Rio M. C. (1992) The breast cancer-associated stromelysin-3 gene is expressed during mouse mammary gland apoptosis. J Cell Biol 119, 997-1002.
87. Lelongt B., Bengatta S., Delauche M., Lund L.R., Werb Z., and Ronco P.M. (2001) Matrix metalloproteinase 9 protects mice from anti-glomerular basement membrane nephritis through its fibrinolytic activity. J Exp Medicine 193, 793-802
88. Levy D. E., Lapierre F., Liang W., Ye W., Lange C. W., Li X., Grobelny D., Casabonne M., Tyrrell D., Holme K., Nadzan A., and Galardy R. E. (1998) Matrix metalloproteinase inhibitors: a structure-activity study. J Med Chem 41, 199-223.
89. Li M., Liu X., Robinson G., Bar-Peled U., Wagner K. U., Young W. S., Hennighausen L., and Furth P. A. (1997) Mammary-derived signals activate programmed cell death during the first stage of mammary gland involution. Proc Natl Acad Sci USA 94, 3425-3430.
90. Liotta L. A., Steeg P. S., and Stetler-Stevenson W. G. (1991) Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64, 327-336.
91. List K., Jensen O. N., Bugge T. H., Lund L. R., Ploug M., Danø K., and Behrendt N. (2000) Plasminogen-independent initiation of the pro-urokinase activation cascade in vivo. Activation of pro-urokinase by glandular kallikrein (mGK-6) in plasminogen-deficient mice. Biochemistry 39, 508-515.
92. Liu Z., Zhou X., Shapiro S. D., Shipley J. M., Twining S. S., Diaz L. A., Senior R. M., and Werb Z. (2000) The serpin alphal-proteinase inhibitor is a critical substrate for gelatinase B/MMP-9 in vivo. Cell 102, 647-655.
93. Lohi J., Wilson C. L., Roby J. D., and Parks W. C. (2001) Epilysin, a novel human matrix metalloproteinase (MMP-28) expressed in testis and keratinocytes and in response to injury. J Biol Chem 276, 10134-10144.
94. Look M. P. and Foekens J. A. (1999) Clinical relevance of the urokinase plasminogen activator system in breast cancer. APMIS 107, 150-159.
95. Lund L. R., Bjørn S. F., Sternlicht M. D., Nielsen B. S., Solberg H., Usher P. A., Osterby R., Christensen I. J., Stephens R. W., Bugge T. H., Danø K., and Werb Z. (2000) Lactational competence and involution of the mouse mammary gland require plasminogen. Development 127, 4481-4492.
96. Lund L. R., Ellis V., Rønne E., Pyke C., and Danø K. (1995) Transcriptional and post-transcriptional regulation of the receptor for urokinase-type plasminogen activator by cytokines and tumour promoters in the human lung carcinoma cell line A549. Biochem J 310, 345-352.
97. Lund L. R., Georg B., Nielsen L. S., Mayer M., Danø K., and Andreasen P. A. (1988) Plasminogen activator inhibitor type 1: Cell-specific and differentiation-induced expression and regulation in human cell lines, as determined by enzyme-linked immunosorbent assay. Mol Cell Endocrinol 60, 43-53.
98. Lund L. R., Rømer J., Thomasset N., Solberg H., Pyke C., Bissell M. J., Danø K., and Werb Z. (1996) Two distinct phases of apoptosis in mammary gland involution: proteinase-independent and -dependent pathways. Development 122, 181-193.
99. Lund L. R., Rønne E., Roldan A. L., Behrendt N., Rømer J., Blasi F., and Danø K. (1991) Urokinase receptor mRNA level and gene transcription are strongly and rapidly increased by phorbol myristate acetate in human monocyte-like U937 cells. J Biol Chem 266, 5177-5181.
100. Mackman N., Sawdey M. S., Keeton M. R., and Loskutoff D. J. (1993) Murine tissue factor gene expression in vivo: Tissue and cell specificity and regulation by lipopolysaccharide. Am J Pathol 143, 76-84.
101. Madlener M., Mauch C., Conca W., Brauchle M., Parks W. C., and Werner S. (1996) Regulation of the expression of stromelysin-2 by growth factors in keratinocytes: Implications for normal and impaired wound healing. Biochem J 320, 659-664.
102. Madlener M., Parks W. C., and Werner S. (1998) Matrix metalloproteinases (MMP'S) and their physiological inhibitors (TIMPs) are differentially expressed during excisional skin wound repair. Exp Cell Res 242, 201-210.
103. Maguire T., Chin D., Soutar D., and Duffy M. J. (2000) Low levels of urokinase plasminogen activator components in basal cell carcinoma of the skin. Int J Cancer 85, 457-459.
104. Mohan R., Chintala S.K., Jung J.C., Villar W.V.L., McCabe F., Russo L.A., Lee Y., McCarthy B.E., Wollenberg K.R., Jester J.V., Wang M., Welgus H.G., Shipley J.M., Senior R.M., and Fini M.E. (2002) Matrix metalloproteinase gelatinase B (MMP-9) coordinates and effects epithelial regeneration. J Biol Chem, 277, 2065-2072.
105. Masson R., Lefebvre O., Noel A., Fahime M. E., Chenard M. P., Wendling C., Kebers F., LeMeur M., Dierich A., Foidart J. M., Basset P., and Rio M. C. (1998) In vivo evidence that the stromelysin-3 metalloproteinase contributes in a paracrine manner to epithelial cell malignancy. J Cell Biol 140, 1535-1541.
106. Mayer M., Lund L. R., Riccio A., Skouv J., Nielsen L. S., Stacey S. N., Danø K., and Andreasen P. A. (1988) Plasminogen activator inhibitor type-1 protein, mRNA and gene transcription are increased by phorbol esters in human rhabdomyosarcoma cells. J Biol Chem 263, 15688-15693.
107. Mazzieri R., Masiero L., Zanetta L., Monea S., Onisto M., Garbisa S., and Mignatti P. (1997) Control of type IV collagenase activity by components of the urokinaseplasmin system: a regulatory mechanism with cellbound reactants. EMBO J 16, 2319-2332.
108. McDonnell S., Navre M., Coffey R. J., and Matrisian L. M. (1991) Expression and localization of the matrix metalloproteinase pump-1 (MMP-7) in human gastric and colon carcinomas. Mol Carcinog 4, 527-533.
109. Miller S. J., Jensen P. J., Dzubow L. M., and Lazarus G. S. (1992) Urokinase plasminogen activator is immunocytochemically detectable in squamous cell but not basal cell carcinomas. J Invest Dermatol 98, 351-358.
110. Mingers A. M., Heimburger N., Zeitler P., Kreth H. W., and Schuster V. (1997) Homozygous type I plasminogen deficiency. Semin Thromb Hemost 23, 259-269.
111. Mingers A. M., Philapitsch A., Zeitler P., Schuster V., Schwarz H. P., and Kreth H. W. (1999) Human homozygous type I plasminogen deficiency and ligneous conjunctivitis. APMIS 107, 62-72.
112. Mohan R., Chintala S.K., Jung J.C., Villar W.V.L., McCabe F., Russo L.A., Lee Y., McCarthy B.E., Wollenberg K.R., Jester J.V., Wang M., Welgus H.G., Shipley J.M., Senior R.M., and Fini M.E. (2002) Matrix Metalloproteinase Gelatinase B (MMP-9) Coordinates and Effects Epithelial Regeneration. J Biol Chem 277, 2065-2072.
113. Morioka S., Jensen P. J., and Lazarus G. S. (1985) Human epidermal plasminogen activator. Characterization, localization, and modulation. Exp Cell Res 161, 364-372.
114. Morioka S., Lazarus G. S., Baird J. L., and Jensen P. J. (1987) Migrating keratinocytes express urokinase-type plasminogen activator. J Invest Dermatol 88, 418-423.
115. Murphy G., Atkinson S., Ward R., Gavrilovic J., and Reynolds J. J. (1992) The role of plasminogen activators in the regulation of connective tissue metalloproteinases. Ann N Y Acad Sci 667, 1-12.
116. Nagase H. and Woessner J. F. (1999) Matrix metalloproteinases. J Biol Chem 274, 21491-21494.
117. Nielsen B. S., Sehested M., Kjeldsen L., Borregaard N., Rygaard J., and Danø K. (1997) Expression of matrix metalloprotease-9 in vascular pericytes in human breast cancer. Lab Invest 77, 345-355.
118. Nielsen B. S., Sehested M., Timshel S., Pyke C., and Danø K. (1996b) Messenger RNA for urokinase plasminogen activator is expressed in myofibroblasts adjacent to cancer cells in human breast cancer. Lab Invest 74, 168-177.
119. Nielsen B. S., Timshel S., Kjeldsen L., Sehested M., Pyke C., Borregaard N., and Danø K. (1996a) 92 kDa type IV collagenase (MMP-9) is expressed in neutrophils and macrophages but not in malignant epithelial cells in human colon cancer. Int J Cancer 65, 57-62.
120. Nielsen B. S., Rank F., Lopez J. M., Balbin M., Vizoso F., Lund L. R., Danø K., and Lopez O. (2001a) Collagenase-3 expression in breast myofibroblasts as a molecular marker of transition of ductal carcinoma in situ lesions to invasive ductal carcinomas. Cancer Res 61, 7091-7100.
121. Nielsen B.S., Sehested M., Duun S., Rank F., Timshel S., Rygaard J., Johnsen M., Danø K. (2001b) Urokinase plasminogen activator is localized in stromal cells in ductal breast cancer. Lab Invest 81, 1485-1501.
122. Noël A., Hajitou A., L'Hoir C., Maquoi E., Baramova E., Lewalle J. M., Remacle A., Kebers F., Brown P., Calberg-Bacq C. M., and Foidart J. M. (1998) Inhibition of stromal matrix metalloproteases: effects on breast-tumor promotion by fibroblasts. Int J Cancer 76, 267-273.
123. Okada A., Bellocq J. P., Rouyer N., Chenard M. P., Rio M. C., Chambon P., and Basset P. (1995) Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas. Proc Natl Acad Sci USA 92, 2730-2734.
124. Ossowski L., Clunie G., Masucci M. T., and Blasi F. (1991) In vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion. J Cell Biol 115, 1107-1112.
125. Ostrowski L. E., Finch J., Krieg P., Matrisian L., Patskan G., O'Connell J. F., Phillips J., Slaga T. J., Breathnach R., and Bowden G. T. (1988) Expression pattern of a gene for a secreted metalloproteinase during late stages of tumor progression. Mol Carcinog 1, 13-19.
126. Otani Y., Okazaki I., Arai M., Kameyama K., Wada N., Maruyama K., Yoshino K., Kitajima M., Hosoda Y., and Tsuchiya M. (1994) Gene expression of interstitial collagenase (matrix metalloproteinase 1) in gastrointestinal tract cancers. J Gastroenterol 29, 391-397.
127. Owens D. M., Wei S., and Smart R. C. (1999) A multihit, multistage model of chemical carcinogenesis. Carcinogenesis 20, 1837-1844.
128. Park H. I., Ni J., Gerkema F. E., Liu D., Belozerov V. E., and Sang Q. X. A. (2000) Identification and characterization of human endometase (matrix metalloproteinase-26) from endometrial tumor. J Biol Chem 275, 20540-20544.
129. Pedersen, H., Brünner, N., Francis, D., Osterlind, K., Rønne, E., Hansen, H. H., Danø, K., and Grøndahl-Hansen, J. (1994) Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res 54, 4671-4675.
130. Pei D. and Weiss S. J. (1995) Furin-dependent intracellular activation of the human stromelysin- 3 zymogen. Nature 375, 244-247.
131. Pei D. and Weiss S. J. (1996) Transmembrane-deletion mutants of the membrane-type matrix metalloproteinase-1 process progelatinase A and express intrinsic matrix-degrading activity. J Biol Chem 271, 9135-9140.
132. Pepper M. S., Montesano R., Mandriota S. J., Orci L., and Vassalli J. D. (1996) Angiogenesis: a paradigm for balanced extracellular proteolysis during cell migration and morphogenesis. Enzyme Protein 49, 138-162.
133. Pepper M. S., Sappino A. P., Montesano R., Orci L., and Vassalli J. D. (1992) Plasminogen activator inhibitor-1 is induced in migrating endothelial cells. J Cell Physiol 153, 129-139.
134. Pepper M. S., Sappino A. P., Stocklin R., Montesano R., Orci L., and Vassalli J. D. (1993) Upregulation of urokinase receptor expression on migrating endothelial cells. J Cell Biol 122, 673-684.
135. Pepper M. S., Vassalli J. D., Montesano R., and Orci L. (1987) Urokinase-type plasminogen activator is induced in migrating capillary endothelial cells. J Cell Biol 105, 2535-2541.
136. Picone R., Kajtaniak E. L., Nielsen L. S., Behrendt N., Mastronicola M. R., Cubellis M. V., Stoppelli M. P., Pedersen S., Danø K., and Blasi F. (1989) Regulation of urokinase receptors in monocytelike U937 cells by phorbol ester phorbol myristate acetate. J Cell Biol 108, 693-702.
137. Plesner T., Ploug M., Ellis V., Rønne E., Høyer-Hansen G., Wittrup M., Pedersen T. L., Tscherning T., Danø K., and Hansen N. E. (1994) The receptor for urokinase-type plasminogen activator and urokinase is translocated from two distinct intracellular compartments to the plasma membrane on stimulation of human neutrophils. Blood 83, 808-815.
138. Ploplis V. A., Carmeliet P., Vazirzadeh S., Van Vlaenderen I., Moons L., Plow E. F., and Collen D. (1995) Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice. Circulation 92, 2585-2593.
139. Ploug M., Rønne E., Behrendt N., Jensen A. L., Blasi F., and Danø K. (1991) Cellular receptor for urokinase plasminogen activator. Carboxyl- terminal processing and membrane anchoring by glycosyl- phosphatidylinositol. J Biol Chem 266, 1926-1933.
140. Ploug M., Østergaard S., Gardsvoll H., Kovalski K., HolstHansen C., Holm A., Ossowski L., Danø K. (2001) Peptide-derived antagonists of the urokinase receptor. Affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation. Biochemistry 40, 12157-12168.
141. Polette M., Clavel C., Muller D., Abecassis J., Binninger I., and Birembaut P. (1991) Detection of mRNAs encoding collagenase I and stromelysin 2 in carcinomas of the head and neck by in situ hybridization. Invasion Metastasis 11, 76-83.
142. Potten C. S. (1981) Cell replacement in epidermis (keratopoiesis) via discrete units of proliferation. Int Rev Cytol 69, 271-318.
143. Pyke C., Kristensen P., Ralfkiær E., Grøndahl-Hansen J., Eriksen J., Blasi F., and Danø K. (1991) Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol 138, 1059-1067.
144. Pyke C., Ralfkiær E., Huhtala P., Hurskainen T., Danø K., and Tryggvason K. (1992) Localization of messenger RNA for Mr 72,000 and 92,000 type IV collagenases in humari skin cancers by in situ hybridization. Cancer Res 52, 1336-1341.
145. Pyke C., Ralfkiær E., Tryggvason K., and Danø K. (1993a) Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer. Am J Pathol 142, 359-365.
146. Pyke C., Græm N., Ralfkiær E., Rønne E., Høyer-Hansen G., Brünner N., and Danø K. (1993b) Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma. Cancer Res 53, 1911-1915.
147. Pyke C., Ralfkiær E., Rønne E., Høyer-Hansen G., Kirkeby L., and Danø K. (1994) Immunohistochemical detection of the receptor for urokinase plasminogen activator in human colon cancer. Histopathology 24, 131-138.
148. Quax P. H., Pedersen N., Masucci M. T., Weening-Verhoeff E. J., Danø K., Verheijen J. H., and Blasi F. (1991) Complementation between urokinase-producing and receptor-producing cells in extracellular matrix degradation. Cell Regulation 2, 793-803.
149. Reiners J. J., Nesnow S., and Slaga T. J. (1984) Murine susceptibility to two-stage skin carcinogenesis is influenced by the agent used for promotion. Carcinogenesis 5, 301-307.
150. Reiners J. J. and Slaga T. J. (1983) Effects of tumor promoters on the rate and commitment to terminal differentiation of subpopulations of murine keratinocytes. Cell 32, 247-255.
151. Riethmüller G. and Klein C.A. (2001) Early cancer cell dissemination and late metastatic relapse: Clinical reflections and biological approaches to the dormancy problem in patients. Sem. Cancer Biol. 11, 307-311.
152. Risse B. C., Brown H., Lavker R. M., Pearson J. M., Baker M. S., Ginsburg D., and Jensen P. J. (1998) Differentiating cells of murine stratified squamous epithelia constitutively express plasminogen activator inhibitor type 2 (PAI-2). Histochem Cell Biol 110, 559-569.
153. Roldan A. L., Cubellis M. V., Masucci M. T., Behrendt N., Lund L. R., Danø K., Appella E., and Blasi F. (1990) Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J 9, 467-474.
154. Rose-John S., Furstenberger G., Krieg P., Besemfelder E., Rincke G., and Marks F. (1988) Differential effects of phorbol esters on c-fos and c-myc and ornithine decarboxylase gene expression in mouse skin in vivo. Carcinogenesis 9, 831-835.
155. Rørth P., Nerlov C., Blasi F., and Johnsen M. (1990)
156. Saarialho-Kere U. K., Kovacs S. O., Pentland A. P., Olerud J. E., Welgus H. G., and Parks W. C. (1993) Cell-matrix interactions modulate interstitial collagenase expression by human keratinocytes actively involved in wound healing. J Clin Invest 92, 2858-2866.
157. Saarialho-Kere U. K., Pentland A. P., Birkedal-Hansen H., Parks W. C., and Welgus H. G. (1994) Distinct populations of basal keratinocytes express stromelysin-1 and stromelysin-2 in chronic wounds. J Clin Invest 94, 79-88.
158. Saarialho-Kere U. K., Vaalamo M., Puolakkainen P., Airola K., Parks W. C., and Karjalainen-Lindsberg M. L. (1996) Enhanced expression of matrilysin, collagenase, and stromelysin-1 in gastrointestinal ulcers. Am J Pathol 148, 519-526.
159. Saksela O. and Rifkin D. B. (1988) Cell-associated plas minogen activation: regulation and physiological functions. Annu Rev Cell Biol 4, 93-126.
160. Salo T., Makela M., Kylmaniemi M., Autio-Harmainen H., and Larjava H. (1994) Expression of matrix metalloproteinase-2 and -9 during early human wound healing. Lab Invest 70, 176-182.
161. Sappino A. P., Belin D., Huarte J., Hirschel-Scholz S., Saurat J. H., and Vassalli J. D. (1991) Differential protease expression by cutaneous squamous and basal cell carcinomas. J Clin Invest 88, 1073-1079.
162. Sappino A. P., Huarte J., Belin D., and Vassalli J. D. (1989) Plasminogen activators in tissue remodeling and invasion: mRNA localization in mouse ovaries and implanting embryos. J Cell Biol 109, 2471-2479.
163. Sato H., Takino T., Okada Y., Cao J., Shinagawa A., Yamamoto E., and Seiki M. (1994) A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 370, 61-65.
164. Schäfer B. M., Maier K., Eickhoff U., Bechtel M., and Kramer M. D. (1996) alpha 2-Antiplasmin and plasminogen activator inhibitors in healing human skin wounds. Arch Dermatol Res 288, 122-128.
165. Schäfer B. M., Maier K., Eickhoff U., Todd R. F., and Kramer M. D. (1994) Plasminogen activation in healing human wounds. Am J Pathol 144, 1269-1280.
166. Schmeller W. and Gaber Y. (2000) Surgical removal of ulcer and lipodermatosclerosis followed by split-skin grafting (shave therapy) yields good long-term results in 'non-healing' venous leg ulcers. Acta Derm Venereol 80, 267-271.
167. Schott D., Dempfle C. E., Beck P., Liermann A., Mohr-Pennert A., Goldner M., Mehlem P., Azuma H., Schuster V., Mingers A. M., Schwarz H. P., and Kramer M. D. (1998) Therapy with a purified plasminogen concentrate in an infant with ligneous conjunctivitis and homozygous plasminogen deficiency. N Engl J Med 339, 1679-1686.
168. Schuster V., Mingers A. M., Seidenspinner S., Nussgens Z., Pukrop T., and Kreth H. W. (1997) Homozygous mutations in the plasminogen gene of two unrelated girls with ligneous conjunctivitis. Blood 90, 958-966.
169. Schuster V., Zeitler P., Seregard S., Ozcelik U., Anadol D., Luchtman-Jones L., Meire F., Mingers A. M., Schambeck C., and Kreth H. W. (2001) Homozygous and compound-heterozygous type I plasminogen deficiency is a common cause of ligneous conjunctivitis. Thromb Haemost 85, 1004-1010.
170. Seghezzi G., Marelli R., Mandriota S. J., Nolli M. L., Mazzieri R., and Mignatti P. (1996) Tumor cell-conditioned medium stimulates expression of the urokinase receptor in vascular endothelial cells. J Cell Physiol 169, 300-308.
171. Seiffert D., Ciambrone G., Wagner N. V., Binder B. R., and Loskutoff D. J. (1994) The somatomedin B domain of vitronectin. Structural requirements for the binding and stabilization of active type 1 plasminogen activator inhibitor. J Biol Chem 269, 2659-2666.
172. Shapiro R. L., Duquette J. G., Roses D. F., Nunes I., Harris M. N., Kamino H., Wilson E. L., and Rifkin D. B. (1996) Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (uPA)-deficient and wild-type mice: cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals. Cancer Res 56, 3597-3604.
173. Shiomi H., Eguchi Y., Tani T., Kodama M., and Hattori T. (2000) Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma. Am J Pathol 156, 567-575.
174. Singer A. J. and Clark R. A. (1999) Cutaneous wound healing. N Engl J Med 341, 738-746.
175. Slaga T. J., Fischer S. M., Weeks C. E., Klein-Szanto A. J., and Reiners J. (1982) Studies on the mechanisms involved in multistage carcinogenesis in mouse skin. J Cell Biochem 18, 99-119.
176. Solberg H., Ploug M., Høyer-Hansen G., Nielsen B. S., and Lund L. R. (2001) The murine receptor for urokinase-type plasminogen activator is primarily expressed in tissues actively undergoing remodeling. J Histochem Cytochem 49, 237-246.
177. Spiers E. M., Lazarus G. S., and Lyons-GiorDanø B. (1996) Expression of plasminogen activators in basal cell carcinoma. J Pathol 178, 290-296.
178. Stacey M. C., Burnand K. G., Mahmoud-Alexandroni M., Gaffney P. J., and Bhogal B. S. (1993) Tissue and urokinase plasminogen activators in the environs of venous and ischaemic leg ulcers. Br J Surgery 80, 596-599.
179. Stefansson S. and Lawrence D. A. (1996) The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin. Nature 383, 441-443.
180. Stephens R. W., Nielsen H. J., Christensen I. J., Thorlacius-Ussing O., Sorensen S., Danø K., and Brünner N. (1999) Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J Natl Cancer Inst 91, 869-874.
181. Stephens R. W., Pöllänen J., Tapiovaara H., Leung K. C., Sim P. S., Salonen E. M., Rønne E., Behrendt N., Danø K., and Vaheri A. (1989) Activation of pro-urokinase and plasminogen on human sarcoma cells: A proteolytic system with surface-bound reactants. J Cell Biol 108, 1987-1995.
182. Sternlicht M. D., Lochter A., Sympson C. J., Huey B., Rougier, J. P., Gray J. W., Pinkel D., Bissell M. J., and Werb Z. (1999) The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell 98, 137-146.
183. Sternlicht M. D. and Werb Z. (1997) Extracellular matrix proteinases, in Guidebook to the extracellular matrix and adhesion proteins (Kreis T. and Vale R., eds.), pp. 2-9. Oxford University Press, New York.
184. Stoppelli M. P., Verde P., Grimaldi G., Locatelli E. K., and Blasi F. (1986) Increase in urokinase plasminogen activator mRNA synthesis in human carcinoma cells is a primary effect of the potent tumor promoter, phorbol myristate acetate. J Cell Biol 102, 1235-1241.
185. Takeuchi T., Harris J. L., Huang W., Yan K. W., Coughlin S. R., and Craik C. S. (2000) Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates. J Biol Chem 275, 26333-26342.
186. Talhouk R. S., Bissell M. J., and Werb Z. (1992) Coordinated expression of extracellular matrix-degrading proteinases and their inhibitors regulates mammary epithelial function during involution. J Cell Biol 118, 1271-1282.
187. Teesalu T., Blasi F., and Talarico D. (1998) Expression and function of the urokinase type plasminogen activator during mouse hemochorial placental development. Dev Dyn 213, 27-38.
188. Teesalu T., Masson R., Basset P., Blasi F., and Talarico D. (1999) Expression of matrix metalloproteinases during murine chorioallantoic placenta maturation. Dev Dyn 214, 248-258.
189. Thorsen S. and Philips M. (1984) Isolation of tissue-type plasminogen activator-inhibitor complexes from human plasma. Evidence for a rapid plasminogen activator inhibitor. Biochim Biophys Acta 802, 111-118.
190. Thorsen S., Philips M., Selmer J., Lecander I., and Astedt B. (1988) Kinetics of inhibition of tissue-type and urokinase-type plasminogen activator by plasminogen-activator inhibitor type 1 and type 2. Eur J Biochem 175, 33-39.
191. Tsukifuji R., Tagawa K., Hatamochi A., and Shinkai H. (1999) Expression of matrix metalloproteinase-1, -2 and -3 in squamous cell carcinoma and actinic keratosis. Br J Cancer 80, 1087-1091.
192. Vaalamo M., Karjalainen-Lindsberg M. L., Puolakkainen P., Kere J., and Saarialho-Kere U. (1998) Distinct expression profiles of stromelysin-2 (MMP-10), collagenase-3 (MMP-13), macrophage metalloelastase (MMP-12), and tissue inhibitor of metalloproteinases-3 (TIMP-3) in intestinal ulcerations. Am J Pathol 152, 1005-1014.
193. Vassalli J. D. (1994) The urokinase receptor. Fibrinolysis 8, 172-181.
194. Vassalli J. D., Baccino D., and Belin D. (1985) A cellular binding site for the M(r) 55,000 form of the human plasminogen activator, urokinase. J Cell Biol 100, 86-92.
195. Vassalli J. D., Sappino A. P., and Belin D. (1991) The plasminogen activator/plasmin system. J Clin Invest 88, 1067-1072.
196. Vu T. H. and Werb Z. (2000) Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev 14, 2123-2133.
197. Wei Y., Lukashev M., Simon D. I., Bodary S. C., Rosenberg S., Doyle M. V., and Chapman H. A. (1996) Regulation of integrin function by the urokinase receptor. Science 273, 1551-1555.
198. Wei Y., Waltz D. A., Rao N., Drummond R. J., Rosenberg S., and Chapman H. A. (1994) Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 269, 32380-32388.
199. Werb Z. (1997) ECM and cell surface proteolysis: regulating cellular ecology. Cell 91, 439-442.
200. Werb Z., Vu T. H., Rinkenberger J. L., and Coussens L. M. (1999) Matrix-degrading proteases and angiogenesis during development and tumor formation. APMIS 107, 11-18.
201. Werner S., Peters K. G., Longaker M. T., Fuller-Pace F., Banda M. J., and Williams L. T. (1992) Large induction of keratinocyte growth factor expression in the dermis during wound healing. Proc Natl Acad Sci USA 89, 6896-6900.
202. Werner S. and Smola H. (2001) Paracrine regulation of keratinocyte proliferation and differentiation. Trends Cell Biol 11, 143-146.
203. Werner S., Smola H., Liao X., Longaker M. T., Krieg T., Hofschneider P. H., and Williams L. T. (1994) The function of KGF in morphogenesis of epithelium and reepithelialization of wounds. Science 266, 819-822.
204. Wolf C., Chenard M. P., Durand-de G., Bellocq J. P., Chambon P., and Basset P. (1992) Breast-cancer-associated stromelysin-3 gene is expressed in basal cell carcinoma and during cutaneous wound healing. J Invest Dermatol 99, 870-872.
205. Wolf C., Rouyer N., Lutz Y., Adida C., Loriot M., Bellocq J. P., Chambon P., and Basset P. (1993) Stromelysin 3 belongs to a subgroup of proteinases expressed in breast carcinoma fibroblastic cells and possibly implicated in tumor progression. Proc Natl Acad Sci USA 90, 1843-1847.
206. Wright J. H., McDonnell S., Portella G., Bowden G. T., Balmain A., and Matrisian L. M. (1994) A switch from stromal to tumor cell expression of stromelysin-1 mRNA associated with the conversion of squamous to spindle carcinomas during mouse skin tumor progression. Mol Carcinog 10, 207-215.
207. Yana I. and Weiss S. J. (2000) Regulation of membrane type-1 matrix metalloproteinase activation by proprotein convertases. Mol Biol Cell 11, 2387-2401.
208. Yoshizaki T., Maruyama Y., Sato H., and Furukawa M. (2001) Expression of tissue inhibitor of matrix metalloproteinase-2 correlates with activation of matrix metalloproteinase-2 and predicts poor prognosis in tongue squamous cell carcinoma. Int J Cancer 95, 44-50.
209. Yuspa S. H. (1998) The pathogenesis of squamous cell cancer: lessons learned from studies of skin carcinogenesis. J Dermatol Sci 17, 1-7.
210. Zhou H. M., Bolon I., Nichols A., Wohlwend A., and Vassalli J. D. (2001) Overexpression of plasminogen activator inhibitor type 2 in basal keratinocytes enhances papilloma formation in transgenic mice. Cancer Res 61, 970-976.
211. Zhou H. M., Nichols A., Meda P., and Vassalli J. D. (2000) Urokinase-type plasminogen activator and its receptor synergize to promote pathogenic proteolysis. EMBO J 19, 4817-4826.
212. Ågren M. S. (1999) Matrix metalloproteinases (MMP's) are required for re- epithelialization of cutaneous wounds. Arch Dermatol Res 291, 583-590.
213. Ågren M. S., Eaglstein W. H., Ferguson M. W. J., Harding K. G., Moore K., Saarialho-Kere U. K., and Schultz G. S. (2000) Causes and effects of the chronic inflammation in venous leg ulcers. Acta Derm Venereol 210, 3-17.
214. Ågren M. S., Mirastschijski U., Karlsmark T., and Saarialho-Kere U. K. (2001) Topical synthetic inhibitor of matrix metalloproteinases delays epidermal regeneration of human wounds. Exp Dermatol 10, 337-348.